Latest news articles

Added 2 days ago Drug news

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV NSCLC.

AstraZeneca and MedImmune, its global biologics research and development arm, announced final overall survival (OS) results for the Phase III...

Added 15 days ago Drug news

FDA gives accelerated approval to Lorbrena for ALK-positive metastatic non-small cell lung cancer.- Pfizer.

Pfizer announced that the FDA has approved Lorbrena (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for...

Added 18 days ago Drug news

FDA approves Keytruda + either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous NSCLC- Merck Inc.

Merck Inc., has announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with carboplatin and either paclitaxel...

Search all news articles for Cancer of bronchus or lung
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Load more

Guidelines

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

These updated guidelines on early and locally advanced non-small-cell lung cancer focus on treatment recommendations including follow-up and survivorship.

Added 5 years ago

Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines

Dyspnoea is described as difficult or laboured breathing and is a frequent symptom in advanced cancer patients, with the highest prevalence in lung cancer. Dyspnoea has been demonstrated to be one of the most distressing...

Added 3 years ago

British Thoracic Society guidelines for the investigation and management of pulmonary nodules

The detection of pulmonary nodules is common. In populations undergoing CTscreening and at high risk of lung cancer, nodules are detected in 20–50% of individuals, depending on the size of the cut-off point for reporting a nodule.

Added 3 years ago

Search all guidelines for Cancer of bronchus or lung
 

Journal articles

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy.

This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation.

Added 3 months ago

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.

Here, in this review, we outline the preclinical and clinical data for BRAF and MEK inhibitor combination treatment for NSCLC patients with BRAF V600E mutation.

Added 3 months ago

Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.

Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy.

Added 3 months ago

Search all journal articles for Cancer of bronchus or lung
 

Clinical trials

Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer

The incidence rate of ground-glass opacity (GGO) has been increasing these years. A great number of retrospective studies suggested that sublobar resection was better for some GGO patients.

Added 1 year ago

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

This global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death−ligand 1 [anti-PD-L1] antibody) compared with docetaxel...

Added 1 year ago

Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer (OREX-IA)

The purpose of this study is to determine the outcome of participants with clinical stage IA NSCLC treated by 3 types of surgical resection (wide wedge resection, segmentectomy, or lobectomy) according to the institutional decision-making algorithm

Added 1 year ago

Search all clinical trials for Cancer of bronchus or lung
 
Advances in Precision Cancer Care

Advances in Precision Cancer Care aims to bring you the latest news and some of the most exciting developments in precision cancer care.

Our first reports come from ESMO Congress 2018.

ESMO 2018 | Day 1 highlights

Today’s report come from the Proffered paper session - NSCLC, metastatic, focusing on presentations LBA50 and LBA51 discussing mechanisms of acquired resistance to osimertinib from the phase III trials FLAURA and AURA3, respectively.

CME

Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90

Non-small cell lung cancer: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
2
Registration required
1
Subscription fee
0

Lung cancer: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Cancer of bronchus or lung